AlphAIAlphAI — Financial news for AI agents
rttnews.comSEP 282 min read$CODX

Codexis Partners With SiRNA Drug Developer To Advance Next-Generation RNA Manufacturing

Codexis (CODX) partnered with a siRNA drug developer to evaluate its ECO Synthesis platform for manufacturing RNA therapies. The collaboration will compare the platform's performance with conventional methods, focusing on purity and quality. Codexis aims to advance scalable manufacturing solutions for oligonucleotide therapeutics. The stock is currently trading at $1.36, up 3.41%.

Original reporting
rttnews.com
Published Sep 28, 2026, 5:25 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 28, 2026, 7:24 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Codexis Partners With SiRNA Drug Developer To Advance Next-Generation RNA Manufacturing — source image
Source · rttnews.com
Decision brief

The 30-second read

$CODXBullishLow
01

Why it matters

The collaboration introduces a new manufacturing route that could improve purity and scalability of siRNA drugs, a growing therapeutic class.

02

Market read

A micro‑cap biotech announces a novel manufacturing partnership, offering modest upside potential for CODX and signaling progress in RNA therapeutics production.

03

What to watch

Potential competition from solid‑phase synthesis providers could temper expectations.

Relevance 5/10Novelty 5/10Timing: today

Background

Codexis (CODX) is a protein‑engineering company expanding into RNA manufacturing. The announcement follows its recent TIDES USA 2026 presentation on full‑length siRNA synthesis.

Company-level read

Ticker impact

$CODXBullishMedium confidence
Context

Codexis announced a new partnership to evaluate its ECO Synthesis platform for siRNA manufacturing, a first‑report collaboration that could enhance product quality.

Expected impact

modest upside as investors price in potential revenue and technology leadership

Evidence & confidence

The deal is a fresh, material collaboration for a micro‑cap biotech; no financial terms disclosed, so impact is limited but positive.

Market effects

Sector

Highlights growing interest in enzymatic synthesis for oligonucleotides, may benefit related biotech manufacturers.

Regional

U.S. biotech sector sees incremental innovation signal.

Global

Limited to niche RNA therapeutics supply chain.

Counterpoint

What could challenge this read

Without disclosed financial terms, the partnership may not translate into near‑term revenue, limiting price impact.

Key entities

  • company
    Codexis, Inc.

    US‑listed protein‑engineering firm (ticker CODX).

Read at source← All news

Related articles

AUG 19
$CDXSMedAI 8/10

Codexis (CDXS) Q2 2026 Earnings Call Transcript

Codexis (CDXS) reported Q2 2026 revenue of $14.9M, down from $15.3M in Q2 2025. Product revenue rose to $13.2M, while R&D revenue fell to $1.7M. Net loss narrowed to $12.0M. The company guided full-year revenue to $72M-$76M and maintained a high 60% gross margin target. It plans to invest $25M in a GMP facility and expects a 30-fold increase in siRNA market demand by 2035. CDXS has 14 commercial products and 15 clinical programs in Phase II/III. Management highlighted progress in ECOsynthesis pl

fool.com6 min
AUG 13
$CODXMed

Co-Diagnostics Reports Second Quarter 2026 Financial Results

Co-Diagnostics (Nasdaq: CODX) reported Q2 2026 results for the quarter ended June 30, 2026. Revenue was $0.17M vs $0.16M a year earlier. Operating loss was $6.2M, net loss $6.3M ($1.46/share). Cash was $3.6M. The company said it completed studies and submitted a 510(k) for its Flu A/B and RSV multiplex test, and raised $3.0M via private placement.

prnewswire.com6 min
AUG 13
$CODXMed

Co-Diagnostics, Inc. (CODX): Results of Operations and Financial Condition

Co-Diagnostics, Inc. (CODX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Co-Diagnostics Reports Second Quarter 2026 Financial Results Advancing Commercialization Through FDA Submission, Global Clinical Progress and Manufacturing Expansion Strengthening Integrated Co-Dx PCR Platform Through Scientific Innovation, Cloud Connectivity and AI-

SEC EDGAR 8-K6 min
AUG 13
$CODXMed

Co-Diagnostics submits flu/RSV test after study of more than 1,400 patients

Co-Diagnostics (Nasdaq: CODX) reported Q2 2026 revenue of $0.17 million, up from $0.16 million a year earlier, with a net loss of $6.3 million ($1.46/share) versus a $7.7 million loss in Q2 2025. Cash fell to $3.6 million from $11.9 million. The company said it completed studies for an FDA 510(k) and CLIA waiver for its Flu A/B & RSV PCR test and raised $3.0 million in a private placement.

stocktitan.net6 min
AUG 11
$CDXSMed

CODEXIS, INC. (CDXS): Results of Operations and Financial Condition

CODEXIS, INC. (CDXS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Codexis Reports Second Quarter 2026 Financial Results Reports revenue of $14.9 million for the second quarter of 2026, company reiterates full-year financial guidance Shared new advances in RNA therapeutic manufacturing at TIDES US showing that its ECO Synthesis ® Ma

SEC EDGAR 8-K6 min
AUG 6
$CODXMed

Co-Diagnostics Submits FDA 510(k) Premarket Notification for Upper Respiratory Point-of-Care Test

Co-Diagnostics (Nasdaq: CODX) said it submitted a Dual 510(k) premarket notification with a concurrent CLIA Waiver by Application to the FDA for its Co-Dx PCR Flu A/B & RSV upper respiratory multiplex test on the Co-Dx PCR Pro instrument. The filing follows clinical studies of 1,400 symptomatic patients and analytical work across 27 studies and 10,000+ PCR runs. If granted, the CLIA waiver would enable decentralized point-of-care use; the platform is not yet for sale.

prnewswire.com2 min